109 related articles for article (PubMed ID: 2018380)
1. Preparation and biological characterization of conjugates consisting of ricin and a tumor-specific non-internalizing MAb.
Cogliati T; Brusa P; Canevari S; Caldera M; Mezzanzanica D; Dosio F; Cattel L; Colnaghi MI
Anticancer Res; 1991; 11(1):417-21. PubMed ID: 2018380
[TBL] [Abstract][Full Text] [Related]
2. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
4. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
Li S; Zhang XY; Chen XT; Fan DM; Tan LS; Pan HZ; Huang LQ
Chin Med J (Engl); 1990 May; 103(5):376-9. PubMed ID: 2118053
[TBL] [Abstract][Full Text] [Related]
5. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
6. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin.
Colombatti M; Johnson VG; Skopicki HA; Fendley B; Lewis MS; Youle RJ
J Immunol; 1987 May; 138(10):3339-44. PubMed ID: 2437188
[TBL] [Abstract][Full Text] [Related]
10. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
11. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
12. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of T-2 toxin-conjugated monoclonal antibody to murine thymoma.
Ohtani K; Murakami H; Shibuya O; Kawamura O; Ohi K; Chiba J; Otokawa M; Ueno Y
Jpn J Exp Med; 1990 Apr; 60(2):57-65. PubMed ID: 2384978
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
Sivam G; Pearson JW; Bohn W; Oldham RK; Sadoff JC; Morgan AC
Cancer Res; 1987 Jun; 47(12):3169-73. PubMed ID: 3495329
[TBL] [Abstract][Full Text] [Related]
17. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
[TBL] [Abstract][Full Text] [Related]
20. Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin.
Foxwell BM; Ross WC; Thorpe PE
Behring Inst Mitt; 1984 May; (74):101-7. PubMed ID: 6477350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]